We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Accelr8 and BD Agree on Terms for Technology Development Program for theBACcel™ Rapid Diagnostics Platform
News

Accelr8 and BD Agree on Terms for Technology Development Program for theBACcel™ Rapid Diagnostics Platform

Accelr8 and BD Agree on Terms for Technology Development Program for theBACcel™ Rapid Diagnostics Platform
News

Accelr8 and BD Agree on Terms for Technology Development Program for theBACcel™ Rapid Diagnostics Platform

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Accelr8 and BD Agree on Terms for Technology Development Program for theBACcel™ Rapid Diagnostics Platform"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Accelr8 Technology Corporation has announced that BD (Becton, Dickinson and Company) and Accelr8 have agreed in principle to terms for an agreement with respect to Accelr8’s BACcel™ rapid bacterial diagnostic system.

Under the contemplated agreement, BD will fund an 18-month milestone project starting April 1, 2008. BD will also have the option to license the technology for product development, manufacturing and commercialization for the clinical diagnosis of infectious diseases.

The definitive agreement is expected to be signed before April 30, 2008.

According to David Howson, Accelr8’s president, “BD leads the industry in clinical microbiology, with broad product offerings for classical microbiology as well as molecular diagnostics. We are excited to work with BD as we move into our next phase of BACcel development.”

In other news, Accelr8 noted issuance of its core “Quantum Microbiology™” patent, for which the company previously had announced notice of allowance. Additionally, the company noted acceptance of three scientific presentations for the 108th General Meeting of the American Society for Microbiology to be held June 1-5 in Boston, MA. Subjects to be covered include multiplexed identification of multiple drug resistance mechanisms, rapid Acinetobacter immunoassay performance, and quantitative analysis of bacteria extracted directly from human clinical specimens.

Advertisement